Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Br J Haematol. 2016 Jul 19;175(3):496–504. doi: 10.1111/bjh.14260

Figure 1. Kaplan Meier estimate of overall survival among sorafenib patients (dashed line) and controls (solid line).

Figure 1

In this landmark analysis, only controls alive and without disease relapse at the median date of sorafenib initiation (+68) were included. Patients given sorafenib maintenance had a significantly higher overall survival (OS) compared to controls at 2 years (p=0.029).